A carregar...
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcomes. Bosentan is an oral endothelin-1 receptor antagonist (ERA) that has been shown in a large randomized placebo-controlled trial (BREATHE-1) to be effective at improving exercise tolerance in patients with PAH i...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2725793/ https://ncbi.nlm.nih.gov/pubmed/19688101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|